This achievement is being considered a great milestone in the field of bio-engineering. Google’s prototype lens was first revealed in January. It is designed to measure the level of glucose in the wearer’s tears and communicate the information to a mobile phone or computer. The latest strategy adopted by these market targeting companies is manipulating the stream of healthcare appliances. The boom is endless with the growth of unhealthy adoption of lifestyle. Wearable technology is seen as a key growth sector.
Novartis announced that its eye care division Alcon has entered into an agreement with a division of Google Inc. to in-license its “smart lens” technology for all ocular medical uses. The agreement with Google[x], a team within Google that is devoted to finding new solutions to big global problems, provides Alcon with the opportunity to develop and commercialize Google’s “smart lens” technology with the potential to transform eye care and further enhance Alcon’s pipeline and global leadership in contact lenses and intraocular lenses.
At present, the majority of them do so by testing drops of blood. Consumer demand for innovative ways of doing this is likely to grow as the incidence of diabetes continues to increase. Mr. Jimenez, Novartis Chief Executive, said the smart lenses may also be used can also correct vision in a manner similar to the lenses on auto focus cameras. This will also help cure a lot of eye related diseases. For people living with presbyopia who can no longer read without glasses, the “smart lens” has the potential to provide accommodative vision correction to help restore the eye’s natural auto focus on near objects in the form of an accommodative contact lens or intraocular lens as part of the refractive cataract treatment.